Greenwich LifeSciences (NASDAQ:GLSI) Announces Earnings Results

Greenwich LifeSciences (NASDAQ:GLSI) issued its earnings results on Tuesday. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.06, FiscalAI reports.

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI traded up $0.05 during trading hours on Tuesday, hitting $15.55. 107,206 shares of the stock were exchanged, compared to its average volume of 237,813. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10. The company’s 50 day moving average is $19.16 and its 200 day moving average is $23.53. The firm has a market capitalization of $228.27 million, a P/E ratio of -9.90 and a beta of 1.46.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. HC Wainwright upped their price objective on shares of Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $57.00.

Insider Buying and Selling

In other news, CEO Snehal Patel bought 2,500 shares of the business’s stock in a transaction on Thursday, July 23rd. The stock was purchased at an average price of $13.14 per share, with a total value of $32,850.00. Following the transaction, the chief executive officer directly owned 5,606,602 shares in the company, valued at approximately $73,670,750.28. The trade was a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 5,800 shares of company stock valued at $76,618. Company insiders own 51.47% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Greenwich LifeSciences by 4.9% in the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after buying an additional 13,179 shares during the period. Geode Capital Management LLC increased its stake in Greenwich LifeSciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after acquiring an additional 9,568 shares during the period. State Street Corp increased its stake in Greenwich LifeSciences by 19.3% during the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after acquiring an additional 15,831 shares during the period. Marshall Wace LLP acquired a new position in Greenwich LifeSciences in the 2nd quarter valued at approximately $509,000. Finally, Man Group plc acquired a new position in Greenwich LifeSciences in the 4th quarter valued at approximately $590,000. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.